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In Sudan, oral squamous cell carcinoma (OSCC) has been found to be associated with the use 
of the Sudanese snuff, locally known as toombak. Expression of the cell cycle regulatory 
proteins, p21WAF1, p16INK4a and Cyclin D1 have been found to be changed in OSCCs 
compared to normal oral mucosa (NOM). In this work, we aimed to investigate the expression 
of p21WAF1, p16INK4a and Cyclin D1, in potentially malignant and malignant oral lesions 
related to toombak- use. Formalin fixed, paraffin embedded tissue specimens from 104 
subjects with OSCCs and 20 with oral epithelial dysplasia (OED) from users and non users of 
toombak were studied by immunohistochemistry (IHC). Ten NOM from non-users were 
included as controls. A significant difference in the expression of p21WAF1, p16INK4a and 
Cyclin D1 was found between NOM, OED and OSCC (p<0.001). In the OSCCs, expression 
of p21WAF1 was significantly higher in toombak- users compared to non- users (p<0.001). 
Compared to NOM, the expression of p16INK4a was found to be lower in both OSCCs and 
OED (p<0.001), (p<0.006) respectively. Expression of p16INK4a was found to be significant (p 
= 0.031) when related to the histological differentiation of the OSCCs and particularly in the 
toombak– users (p = 0.040). There was a high expression of Cyclin D1 in the OSCCs 
compared to both NOM and OED (p<0.001), but there was no significant difference between 
toombak- users and non- users. In conclusion, the expression of the cell cycle regulatory 
proteins p21WAF1 and Cyclin D1 was found to be increasing from NOM to OED to OSCCs. 
Patients with OSCCs who were toombak users had high expression of p21 WAF1. Our findings 
suggest that the difference in expression of these proteins may be important in potentially 
malignant and malignant oral lesions. In particular, the findings related to p21WAF1 indicate its 








Cdk  Cycline dependent kinase 
Cdki  Cycline dependent kinase inhibitor 
G0   Gap 0 phase of the cell cycle       
G1  Gap 1 phase of the cell cycle 
G2  Gap 2 phase of the cell cycle 
H&E  Haematoxylin and eosin stain 
IARC   International Agency for Research on Cancer 
IHC:   Immunohistochemistry  
MD   Moderately differentiated squamous cell carcinoma 
NOM  Normal oral mucosa 
OED   Oral epithelial dysphasia 
OSCC   Oral squamous cell carcinoma  
OSCCs Oral squamous cell carcinomas 
PAH   Polycyclic aromatic hydrocarbons 
PD  Poorly differentiated squamous cell carcinoma 
Rb  Retinoblastoma 
S    Syntheses phase of the cell cycle 
SCC  Squamous cell carcinoma 
ST  Smokeless tobacco 
TSNAs  Tobacco-specific nitrosamines  
UICC  International Union Against Cancer 
WD  Well differentiated squamous cell carcinoma 











Oral squamous cell carcinoma (OSCC) is a global health problem. Of the 615,000 new cases 
of head and neck SCCs reported worldwide in year 2000, 300,000 were primary found to 
occur in the oral cavity (Parkin et al., 2005; Kademani, 2007). The overall mortality rate for 
intra-oral SCC is reported to be about 50% (Noonan and Kabani, 2005). In Africa, Sudan has 
a particularly high incidence rate of OSCC (11.60 for males and 6.91 for females) (Idris et al., 
1995b). OSCC has been found to demonstrate a non-uniform pattern of distribution, both 
geographically and demographically, with an alarming number of cases occurring in the 
developing countries (Boyle and Ferlay, 2005; Ferlay et al., 2007). This observation might 
reflect an environmental, cultural and/or habitual influence in the prevalence of this disease 
(Day et al., 2003; Copper et al., 2003). For example, the high incidence rate of OSCC 
reported in Australia and New Zealand, mainly lip SCC, has been suggested to be related to 
solar irradiation (Parkin et al., 1999; Walker et al., 2003). In Sudan, OSCC is strongly 
attributed to the habit of extensive use of toombak – a form of snuff commonly used in Sudan 
(Elbeshir et al., 1989; Idris et al., 1991; Idris et al., 1992; Idris et al., 1994; Idris et al., 1995b). 
 OSCC affects predominately individuals with low socio-economical status. This 
distribution is usually associated with use of tobacco, heavy alcohol consumption and 
deficient diet (Johnson, 1991; Hashibe et al., 2003; Hobdell et al., 2003). The International 
Agency for Research on Cancer (IARC) confirmed that smoking of the various forms of 
tobacco (cigarettes, cigars, pipes, etc) is carcinogenic to humans (IARC, 1986). Other forms 
of tobacco, known as smokeless tobacco (ST), are also reported to be associated with an 






Ministry of Health in 2000, illustrated that tobacco-related cancers are evident in the list of 
the 10 most common cancers (Hamad, 2006).  
 A low intake of fresh fruits and vegetables has been linked to an increased risk of 
OSCC (McLaughlin et al., 1988; De et al., 1999). Although the individual micronutrients 
responsible for that, have not been formally identified, vegetables and fruits that protect 
against oral cancer are rich in -carotene, vitamin C and vitamin E with anti-oxidant 
properties (Walker et al., 2003). 
 
Clinical presentation and diagnosis 
Despite the accessibility of the oral cavity to direct clinical examination, OSCCs are not easily 
detectable (Pereira et al., 2007). Patients with OSCCs usually seek consultation after 
developing severe and persistent pain with the most frequent complaint “irritation/ burning 
sensation” in the mouth. Early OSCC may be painless or associated with only a mild degree 
of irritation. Pain usually occurs when the lesion becomes ulcerated, but sometimes, although 
rarely, a patient might seek consultation because of a “lump in the neck” that represents a 
metastasis from an oral lesion of which the patient may be completely unaware (Silverman et 
al., 2003). The symptoms and signs however, may reflect an identifiable pathological process.  
The common signs and symptoms attributed to OSCCs include; 
 
• Ulceration or erosion: This sign of the disease reflects the destruction of the epithelial 
integrity due to discrepancy in cell maturation, loss of intercellular attachments, and 
disruption of basemen membrane as seen in (Fig.1)  
• Erythema: Illustrates redness reflecting inflammation, thinness and irregularity of 
epithelium.  







• Fixation: Fixation to underlying tissues occurs when abnormally dividing cells invade 
to deeper areas of muscle and bone. 
• Chronicity: Indicating failure to heal. 
• Lymphadenopathy: Hardening and enlargement of regional nodes due to engorgement 
with neoplastic cells that spread by lymphatic vessels. Lymph nodes are usually 
painless and often become fixed because of capsular erosion and local infiltration. 
Tumours that involve marked induration, fixation, and lymphadenopathy are signs of 
advanced cancer.  
 
 
Fig.1. Examples of oral squamous cell carcinoma lesions illustrating destruction of the oral 
mucosa at two different sites (A: Labio-sulcus; B: Buccal pouch) of toombak dipping.  
 
Histological classification/ criteria 
OSCCs are usually characterized by ulcerated appearance, high degree of local invasion 
and a high rate of metastasis to the regional cervical lymph nodes. The histopathological 
features (Fig.2) show variable degree of keratinisation, pleomorphism and mitotic activity. 






into account an assessment of the degree of keratinisation, cellular and nuclear pleomorphism 
and mitotic activity (Barnes L et al., 2005). Accordingly, three grades, based on the degree of 
differentiation of the lesion, have been commonly in use:  
Grade 1 Well differentiated 
Grade 2 Moderately differentiated 
Grade 3 Poorly differentiated 
 
 The well and moderately differentiated OSCCs can be grouped together as low grade 
and poorly differentiated and undifferentiated ones as high grade. Generally, the 
histopathological grading of malignancy has limited impact on the survival rate due to the 
subjective nature of the assessment of the various features involved. Moreover, the cancer 
cells frequently show local recurrence after initial treatment, probably due to microinvasion 
and/or micrometastasis of the tumour cells around the primary site. Therefore, the average 
five-year survival rate of OSCC has not improved over the last few decades and remains as 
poor; 20% to 50%, depending on the clinical stage of the tumour (Casiglia and Woo, 2001). 
The TNM (Tumour, Node and Metastases) staging system which was developed and 
maintained by the International Union Against Cancer (UICC) (Carinci et al., 1999) is a 
universally accepted tool for staging of OSCCs. However, it does not take into account the 
histopathology and the biology of the tumour (Rapidis et al., 1977; Partridge, 1999). 
Therefore, the terms Site (S) and histopathology (P) were added in a staging system denoted 
as STNMP that correlated with survival (Rapidis et al., 1977). However, due to the limited 
prognostic value(s) of the STNMP staging in OSCCs, many patients are still over-or under-
treated, resulting in significant personal and socioeconomic impact (Bankfalvi and Piffko, 






thickness and extracapsular spread of nodal metastases — have not become part of the routine 
TNM classification (Woolgar, 2006).  
 
Fig.2. Histopathological appearance of an oral squamous cell carcinoma lesion (panel A, 
original magnification x150) and (panel B, original magnification x320) showing strands of 
malignant epithelial cells forming keratin pearls in a moderately well differentiated tumour. 
 
Treatment and prognosis 
Despite an intensive research efforts to develop new therapeutic strategies for OSCCs, 
the five-year survival rate of patients with this pathology has not been improved over the past 
3 decades and remains at 20- 50% (Noonan and Kabani, 2005; Ayllon et al., 2008). The 
standard treatment for patients with potentially malignant oral lesions  or with an  aggressive 
malignant oral lesion varies from observations and follow up of patients to complete surgical 
removal of the lesion (Lodi et al., 2004). The combination of surgery/chemotherapy or 
radiotherapy is commonly in use for treatment of OSCCs. These lesions are good candidates 
for gene therapy because primary and recurrent lesions are readily accessible for injection or 








Potentially malignant oral lesions 
Over 90% of the OSCCs are often preceded by a pre-existing potentially malignant lesion 
(Noonan and Kabani, 2005).The terms precursor lesions, premalignant, intra epithelial 
neoplasia and potentially malignant lesions have been used in the literature to broadly 
describe the clinical presentations of these lesions that may have the potential to become 
cancer. All these terms convey the concept of a two-step or multi-step process of cancer 
development. The term “potentially malignant disorders”, is recently recommended to refer to 
these lesions as it conveys that, not all lesions described under this term may transform into 
cancer, but that there is a family of morphological alterations amongst which some may have 
an increased potential for malignant transformation (Warnakulasuriya et al., 2007). Although 
most of the patients with OSCC present without prior diagnosis of a potentially malignant 
lesion, two main types of potentially malignant lesions are well documented: leukoplakias 
(white patches) (Fig.3) and erythroplakias (red patches) (Fig.4), which both are much more 
likely to show histological features of dysplasia and possibility to progress to OSCC (Reichart 
and Philipsen, 2005). It is common to state that OSCCs are often clinically preceded by 
potentially malignant lesions, mainly leukoplakia, although the proportion of the cases that 
develop through clinically recognizable potentially malignant stages is not known (Speight 
and Morgan, 1993). The presence and degree of epithelial dysplasia is generally accepted as 
the best indicator of malignant potential of leukoplakia (Mincer et al., 1972). Although less 
common than leukoplakia, erythroplakia poses a greater threat of transformation into 
malignancy, and the lesions usually demonstrate significant epithelial dysplasia, carcinoma in 
situ or invasive SCC (Barnes L et al., 2005) (Fig.4) A novel binary grading system (high/low 
risk) for OED was compared with the WHO classification system from 2005 (Kujan et al., 






severe dysplasia and from carcinoma in situ, but assessment of moderate dysplasia remained a 
problem. The sensitivity and specificity of the new binary grading system for predicting 
malignant transformation in OED were 85% and 80%, respectively and the accuracy was 82% 
(Kujan et al., 2006).  
 
Fig.3.  This figure illustrates the clinical appearance of two white lesions (leukoplakias) 




Fig.4. This figure demonstrates the clinical appearance of a serious red lesion (erythroplakia) 






The Sudanese toombak 
Smokeless tobacco (ST) constitutes a wide range of habits and products used in many parts of 
the world (Johnson, 1991). Although the WHO reported that habits of snuff dipping/tobacco 
chewing are practiced by millions of people in Africa, most of the information on these habits 
and their relation to oral cancer is either from western Europe, North America and/or South 
East Asia (Johnson, 1991; Boffetta and Parkin, 1994). In Sudan, ST is commonly used in a 
form of oral dipping tobacco locally called toombak which was introduced approximately 
over 400 years ago (Ahmed and Mahgoob, 2007). The tobacco used for the manufacture of 
toombak is of the species Nicotiana rustica (Fig.5), and the fermented ground powder is 
mixed with an aqueous solution of sodium bicarbonate. The resultant product is processed 
into a loose moist form with a strong aroma and its use is widely spread in the country. 
Toombak, or Sudanese snuff, differs from other types of snuff used in Scandinavia and the 
USA when it comes to tobacco species, fermentation and aging, methods of manufacturing, 
pH value, moisture, nicotine, and nitrosamines content (Idris et al., 1998a).  
 
Fig.5. Tobacco plant of the species Nicotiana rustica 
 






prevalence of the habit among the older men in rural areas is close to 50% (Idris et al., 
1998b). Toombak use is uncommon among the females, as it is considered to be a social 
stigma. Albeit, there are some female users in particular older females.  
There are approximately 5 million users of toombak in Sudan (Elbeshir et al., 1989; 
Idris et al., 1994). It has been reported that more than 81% of the toombak users in Sudan do 
not smoke cigarettes (Elbeshir et al., 1989; Idris et al., 1991; Idris et al., 1992; Idris et al., 
1994; Idris et al., 1995b). 
The factors which are believed to have significant adverse health consequences in 
toombak, particularly addiction and oral cancer development, are the pH value and the high 
levels of the tobacco-specific nitrosamines (TSNAs) (Idris et al., 1998a). The toombak pH 
range is 8-11, with a moisture content in the range of  6-60% and nicotine content is from 8 to 
102 mg/g dry weight and TSNAs contents in micrograms (N'-nitrosonornicotine NNN 420-1 
550; 4-(methyl-nitrosamino)-l-(3- pyridyl )-l- butanone NNK 620-7 870; N'-nitrosoanatabine 
NAT 20-290) (Ahmed and Mahgoob, 2007).  
 Compared with snuff from Sweden and USA, toombak contains a 100-fold higher 
levels of the TSNAs (Cogliano et al., 2004), which – together with their metabolites- are 
considered to be the major groups of carcinogens (Idris et al., 1991; Ibrahim et al., 1999; Loro 
et al., 2000; Ibrahim et al., 2002). The metabolites of TSNAs, particularly NNN and NNK are 
found to be present  in the saliva of toombak dippers, as well as in their body fluids (Idris et 
al., 1991; Idris et al., 1992; Idris et al., 1998a).  
 The second highest relative frequency (17%) of OSCCs in Africa, is reported from 
Sudan, which is strongly attributed to extensive use of  toombak (Elbeshir et al., 1989; Idris et 
al., 1991; Idris et al., 1992; Idris et al., 1994; Idris et al., 1995b). .This high relative frequency 






between toombak use and development of oral cancer and the adverse oral health effects 
including increased gingival recession and teeth discoloration (Elbeshir et al., 1989; Idris et 
al., 1991; Idris et al., 1992; Idris et al., 1994; Idris et al., 1995b) (Fig.3). Moreover, it has been 
shown that 80% of the patients with OSCCs are toombak users (Elbeshir et al., 1989; Idris et 
al., 1991; Idris et al., 1992; Idris et al., 1994; Idris et al., 1995a; Idris et al., 1995b). Toombak 
dipping has also been suggested to be associated with neoplasm of salivary glands (Elbeshir et 
al., 1989; Idris et al., 1991; Idris et al., 1992; Idris et al., 1994; Idris et al., 1995b) and is a 
potential risk factor for development of oesophageal and lung cancer (Idris et al., 1994).  
 During toombak dipping, and when a Sudanese individual consumes 1 gram of 
toombak 10 times a day (this is a conservative estimates since 1 gram of toombak lasts only 
15- 30 minutes of average in the oral vestibule), more than 80% of the TSNAs are extracted 
from toombak by saliva and the negative pressure created by the sucking effect of the 
toombak quid placed in the labio-sulcus region. The user in this case will be exposed to an 
average of 11.3 mg of NNN and 23.1 mg of NNK per day (Idris et al., 1991; Idris et al., 
1994). It is possible therefore to claim that in over one year an average toombak user in Sudan 
will be exposed to high levels of these carcinogens, which are high enough to induce OSCCs 
if administered to experimental animals (Hecht et al., 1986; Hoffmann et al., 1996).  
Toombak- users usually develop clinically and histopathologically characteristic lesions 
(leukoplakia) at the site of dipping. Oral leukoplakia caused by ST has been reported in 
Sweden, USA and Sudan (Roed-Petersen and Pindborg, 1973; Jungell and Malmstrom, 1985; 
Greer et al., 1986; Andersson et al., 1989; Daniels et al., 1992; Idris et al., 1996).Chronic 
exposure of the oral cavity to tobacco, often results in the development of potentially 
malignant lesions, mainly leukoplakia, 5–10% of which might undergo malignant 






The Cell cycle 
The cell reproduces through an orderly sequence of events which culminates in the generation 
of two new cells (Blomen and Boonstra, 2007). This cycle of events is known as “the cell 
cycle”. The principle function of the cell cycle is to replicate DNA and to segregate the 
replicated chromosomal DNA into two daughter cells. The cell cycle is divided into 4 major 
phases. The first phase is defined as the gap1 (G1) phase, during which the cell makes the 
decision to either proceed to DNA syntheses or to exit the cell cycle into a quiescent state 
called (G0). Cells in the G0 phase account for the major part of the non-growing, non-
proliferating cells in the human body. Once the decision to start DNA replication has been 
made, the cell becomes irreversibly committed to complete the cell cycle. The time in the late 
G1 phase at which this decision is made is designated the “restriction point” (Pardee, 1989). 
The cell then proceeds to the so called the synthesis (S) phase in which a copy of a cell’s 
DNA is replicated. The cell then, in the gap 2 (G2) phase, is ready to segregate its replicated 
DNA. G1 and G2 phases together provide additional time for the cell to grow and duplicate its 
cytoplasmic organelles. G1, S and G2 phases constitute the inter-phase of cell division, which 
is the period between one mitosis phase and the next one. Segregation of the DNA takes place 
in the mitotic (M) phase, which is divided into four stages (prophase, metaphase, anaphase 
and telophase) depending on the stage of DNA segregation and degree of cytokinesis. The 
progression from the G1SG2MG1 is controlled by a number of proteins (Blomen 
and Boonstra, 2007). This control is essential to ascertain genomic replication without fault 







Fig.6. A schematic overview illustrating the different cell cycle phases 
 
Cell cycle checkpoints 
The cell has developed a process through which it can monitor the cell cycle to ensure proper 
replication and segregation of the DNA. This process consists of 4 checkpoints in the cycle as 
shown in (Fig.6) A checkpoint is defined as a biochemical pathway that ensures dependence 
of one process upon another process that is otherwise biochemically unrelated (Elledge, 
1996). Checkpoints refer usually to points in the cell transitions that ensure the fidelity of cell 
division (Elledge, 1996). Control mechanisms at these checkpoints ensure that chromosomes 
are intact and that each phase of the cell cycle is completed before the succeeding one starts. 
 
Apoptosis 
The process of apoptosis is the genetically regulated form of cell death that permits the 






(Afford and Randhawa, 2000; Loro et al., 2003). The term apoptosis was introduced by John 
Kerr in 1972 (Kerr et al., 1972). Apoptosis is known to be directly stimulated by the p53 
tumour suppressor protein (Balint and Vousden, 2001; Ryan et al., 2001). Stimuli, such as 
DNA damage, activate the p53 protein to induce cell cycle arrest or apoptosis (Bargonetti and 
Manfredi, 2002) and selectively, eliminates stressed or damaged cells and thereby protecting 
the organism from development of cancer. In order to facilitate this process, apoptosis should 
be tightly coupled to the cell cycle checkpoints (King and Cidlowski, 1995). In almost all 
instances of human cancer development, dysregulation of the cell death (apoptosis) and the 
cell proliferation have been found to play a major role in the process of carcinogenesis 
(Carson and Ribeiro, 1993; Wyllie, 1997). 
 
Cell cycle regulatory proteins 
The progression of the cell cycle through the different phases is controlled by proteins called 
cyclines (Sherr, 1993; Hartwell and Kastan, 1994). There are different types of cyclines (A- J) 
each of which acts at a certain phase of the cell cycle. In order for the cyclines to function, 
they have to form complexes with cycline dependent kinases (cdk); cdk1, cdk2….cdk8. 
(Nurse, 1990; Reed, 1992; Sherr, 2000). These complexes are denoted (cdkc). There are three 
subtypes of Cyclin D (D1, D2 and D3) which are expressed through the cell cycle in response 
to mitogenic signals. Together with its catalytic partners cdk4 and cdk6, Cyclin D1 
accelerates G1 progression by phosphorylating the retinoblastoma protein (RB) (Todd et al., 
2002) (Fig.7).  
Cdk activity can be counteracted by the cell cycle inhibitory proteins, called cdk 
inhibitors (cdki) which bind to the complexes of the cycline-cdk and inactivate the cdkc 






been identified, the INK4 family and Cip/Kip family (Vermeulen et al., 2003). The INK 
family is composed of four members: p15INK4b, p16INK4a, p18INK4c, p19INK4d, which 
specifically inactivate the G1 cdk (cdk4 and cdk6). The second family of inhibitors, the 
Cip/Kip family, includes p21WAF1, p27KIP1 and p57KIP2 (Ekholm and Reed, 2000).  
 
Cell cycle regulatory proteins and oral carcinogenesis 
The multistep process of oral carcinogenesis involves functional alterations of the cell cycle 
regulatory proteins combined with the escape from the cellular quiescence and apoptotic 
signalling pathways (Todd et al., 2002; Jayasurya et al., 2005). Uncontrolled cell proliferation 
is the hallmark of cancer development, and tumour cells have typically acquired damage to 
genes that directly regulate their cell cycles (Pavelic et al., 1996; Lundberg and Weinberg, 
1999). Dysregulation of the cell cycle, apoptosis and the cell-cell/cell-matrix adhesions are 
the pathways mainly influencing this multistage event (Lo et al., 2007). Several studies have 
shown altered patterns of expression of the cell cycle regulators in OSCCs (Pavelic et al., 
1996; Pande et al., 1998; Pande et al., 2002). The two well-defined pathways that are shown 
to be prominently altered in a variety of cancers including OSCCs are the cell cycle regulatory 
pathways led by either p53 or Rb genes (Jayasurya et al., 2005).  Therefore, these two 
pathways are considered as  important interconnected biochemical pathways that are 
frequently found to be changed in OSCCs and were suggested to be  a near universal target in 







Fig.7. A schematic overview showing part of the cell cycle and the essential steps involved in 
the cell cycle regulation. The role of the major components of the p53 and the retinoblastoma 
(Rb) pathways and the site of the activity of the regulatory cdk/cyclin complexes is also 
indicated. (: activation, : inhibition, MS: mitogenic signal) 
  
p21WAF1 
 p21WAF1, a cell cycle regulatory protein encoded by the p21WAF1gene, is the first 
identified inhibitor of the cyclin/cyclin dependent kinase (cdk) complex (Harada and Ogden, 
2000). p21WAF1attracted a great deal of attention because it sheds further light on the function 
of the p53 as well as it is involved in some interactions and biological functions, going far 
beyond  the control of the cell cycle (Dotto, 2000). It is believed that the inhibitory effects on 
the cell division by p21WAF1 are closely related to the cell differentiation, senescence, 
cancerous change of normal cells, regulation and induction of apoptosis involving p53 
(Harada and Ogden, 2000). Several p21WAF1 mutations have been reported in human cancers, 






(Roninson, 2002).  
The cdk inhibitor p21WAF1 is a downstream component of the p53 pathway and it mediates the 
cell cycle arrest after genotoxic stress (el-Deiry et al., 1993; Yeudall and Jakus, 1995; Harada 
and Ogden, 2000; Dotto, 2000). Therefore, p21WAF1 has a tumour suppressor ability, 
demonstrated in OSCC model experiments, in which overexpression of the p21WAF1 
suppresses tumour growth (Cardinali et al., 1998). However, several functions of the p21WAF1 
are likely to promote carcinogenesis and tumour progression, such as its ability to inhibit 
apoptosis and the expression of genes involved in the quality control of mitosis, and to 
promote the assembly of active cyclin-cdk complexes (Roninson, 2002). Furthermore, it has 
been reported that p21WAF1 expression increases in OSCC (Erber et al., 1997; Agarwal et al., 
1998; Tatemoto et al., 1998; Nemes et al., 2005), suggesting that this protein alone may not be 
sufficient to arrest the cell cycle and inhibit tumour cell growth (Ng et al., 1999; Regezi et al., 
1999; Yuen et al., 2001; Yanamoto et al., 2002). In addition, p21WAF1 overexpression has 
been reported in lower lip SCCs (Horta et al., 2007). 
 
p16INK4a 
 Since its discovery as an inhibitor of the cdk 4/ 6, the tumour suppressor p16INK4a 
continued to gain attention in cancer research (Kato et al., 2000). p16INK4a is one of the direct 
links between cell-cycle control and cancer development (Serrano, 1997). The mechanisms 
that regulate p16INK4a have been characterized (Serrano, 1997). Changes that are commonly 
observed in human cancers are related to mutation, homozygous deletions and/or 
hypermethylations of the promoter region of the tumour suppressor gene p16INK4a. 
Inactivation of the p16INK4a gene through these mechanisms may lead to loss of the gene 






tumour cell lines first suggested an important role for p16INK4 in human carcinogenesis. This 
initial genetic evidence was subsequently strengthened by numerous studies demonstrating 
inactivation of the p16INK4a in several human cancers, and it is now believed that loss of the 
p16INK4a is an early and often critical event in tumour progression (Rocco and Sidransky, 
2001).  
 Inactivation of the p16INK4a was found to occur at the early stage of the multistep 
process of oral tumourigenesis (Vairaktaris et al., 2007) and is a frequent event in squamous 
cell carcinomas of the head and neck (Reed et al., 1996; Ogawa et al., 2006). Aberrant 
methylation of p16INK4a is relatively frequently observed in OSCC. This also suggests that 
loss of p16INK4a expression is a true oncogenic event (Auerkari, 2006). It has been found that 
head and neck squamous cell carcinomas were p16INK4a immunostaining- negative and that 
the absence of p16INK4a immunostaining was correlated with a homozygous deletion of the 
p16INK4a gene or hypermethylation of the p16INK4a gene promoter (Reed et al., 1996).  
 
Cyclin D1 
 Cyclin D1 is expressed through the cell cycle in response to mitogenic stimulation and 
it interacts with cdk4 and cdk6 (Todd et al., 2002). Ultimately, it contributes to the 
phosphorylation of the retinoblastoma gene product (pRb) and is also necessary for the G0/G1 
transition (Todd et al., 2002) (Fig.7). In the early G1 phase, pRb is present in a 
hypophosphorylated form that binds to and inactivates some of the E2F transcription factors 
that have a fundamental role in preparing the nucleus for DNA replication. Hence, until pRb 
is fully phosphorylated, E2F cannot be released and DNA synthesis cannot take place 
(Weinberg, 1995). 






reported to be overexpressed in OSCCs (Sathyan et al., 2006; Wang et al., 2006). 
Overexpression of Cyclin D1 has been shown to occur early during development of OSCCs 
(Schoelch et al., 1999; Koontongkaew et al., 2000; Fabbrocini et al., 2000; Jayasurya et al., 
2005). Experimental evidence has also suggested that Cyclin D1 functions as an oncogene 
and that increased expression of Cyclin D1 accelerates the G 1 to S phase transition and likely 








Aims of the study 
 
The objective of the present study is to evaluate the expression of the cell cycle regulatory 
proteins p21WAF1, p16INK4a and Cyclin D1, in oral epithelial dysplasias and oral squamous cell 










One hundred and twenty four consecutive patients (85 males and 39 females, mean 
age: 52.95, SD: 17.70 and range 22- 96 years) with potentially malignant or malignant oral 
mucosal lesions were included in this study. All the patients attended the Department of Oral 
and Maxillofacial Surgery, Khartoum Dental Teaching Hospital, University of Khartoum, 
Sudan. The patients had not been previously treated. Specimens of normal oral mucosa 
(NOM) were obtained from 10 healthy volunteers, who had no evidence of any oral mucosal 
lesions and who attended the same hospital for removal of their lower wisdom teeth. The 
patients were interviewed on oral habits such as toombak dipping, cigarette smoking and 
alcohol usage. The majority of the patients (n=89) (71%) were habitual consumers toombak 
and 6 (30%) in the OED group used alcohol, while no toombak/ or alcohol user was found 
among the ten patients with NOM, but only  2 of them (20%) were smokers. Among the 
OSCC group only 17.3% (18/104) used alcohol. All participants signed an informed written 





From each patient, a surgical tissue sample of the lesion was taken, fixed in 10% 
buffered formalin and embedded in paraffin. The diagnosis of the study samples was based on 
clinical examination and histopathological analysis of the tissue specimens at The Department 
of histopathology, National Health Laboratory, Khartoum, Sudan. All the OED and OSCC 







 From all the formalin-fixed, paraffin-embedded tissue specimens (n=134), serial 
sections (4-5µm thick) were cut and processed for routine histopathological and subsequent 
immunohistochemical (IHC) studies. Haematoxylin and eosin (H&E)-stained sections were 
examined under a light microscope and diagnosed according to the WHO criteria for 
histological classification of tumours of the oral cavity (Barnes et al., 2005). OED (n=20), 
were obtained from the following sites: gingiva (n=10), floor of the mouth (n=2), and buccal 
mucosa (n=8), and were graded as mild [15% (n=3)], moderate/ severe [85% (n=17))] based 
on the WHO criteria (Barnes et al., 2005). Biopsies of OSCC (n=104), were obtained during 
surgery from the primary intra-oral tumours from the following sites: Mucosa of the lip 
(n=22), gingiva (n=26), tongue (n=7), floor of the mouth (n=20), buccal mucosa (n=19), and 
palate (n=11). The biopsies (approximately 10 mm in diameter) were taken from the deeper 
part of the tissue routinely excised, half way between the periphery and the centre of the 
tumour mass. Eighty nine of the OSCCs were well differentiated (WD) (85.6%), 11 were 




The samples obtained from the subjects were used to assess the expressions of 
p21WAF1, p16INK4a, and Cyclin D1 using IHC. Sections (on silane- coated slides) were 
deparaffinised in xylene and dehydrated through graded alcohol and washed in Tris-buffered 
saline (TBS; pH 7.6). Cyclin D1 and p21WAF1 antigen retrieval procedure was performed with 
TRIS/EDTA buffer (pH 9.0) using a microwave oven at high power setting (900W, for a 
period of 5-7 min) followed by a low power setting (300 W for 15 min). p16INK4a antigen 
retrieval was carried out in a water bath at 95°C for 60 min, using an epitope retrieval solution 






20 min at room temperature and washing in TBS (10 min), the sections were incubated with 
the Dako peroxidase block, 0.03% hydrogen peroxide containing sodium azide (Code K4007) 
for 5 min to eliminate endogenous peroxidase activity. After washing in TBS for 10 min, the 
sections were then incubated with the relevant primary antibodies for 60 min on the DAKO 
Autostainer Universal Staining En VisionTM+ System (Dako A/s, Copenhagen, Denmark) 
using antibodies against p21WAF1 (Clone DCS-60.2 dilution 1:100, Oncogene Research 
Products, Cambridge. GB), Cyclin D1 (NCL-CYCLIN D1, Clone DCS-6, dilution 1:100 in 
Dako Antibody Diluent; Novocastra Laboratories Ltd., Newcastle-Upon-Tyne, UK). The 
p16INK4a monoclonal antibody E6H4, (dilution 1:25 Dako Cytomation, Copenhagen, 
Denmark) was used as the primary antibody to detect p16INK4a protein expression.  
 The secondary antibody and visualization were provided by a p16INK4a research kit 
(OA315 Dako Cytomation Denmark A/S). Briefly, a polymer agent (dextran conjugated 
polyclonal goat anti-mouse immunoglobulin) was used as the second antibody and 3,3’-
diaminobenzidine tetra-hydrochloride was used as a chromogen.  
After cooling for 20 min at room temperature and washing in TBS (10 min), the 
sections were incubated with the En Vision Horseradish peroxidase (DAB) for 30 min, 
washed twice in TBS for 5 min each, and further developed twice with the DAB + chromogen 
for 5 min each. The sections were then counterstained with haematoxylin, rinsed in tap water 
for 10 min, rehydrated and mounted using the Eukitt mounting medium. Cases in which the 
primary antibody was omitted and substituted with TBS served as negative controls. Tissue 









Evaluation of the immunohistochemistry 
 
Sections were examined for p21WAF1, p16INK4a and Cyclin D1 positive nuclear staining using a 
light microscope. Staining of p21WAF1 and Cyclin Dl was present exclusively in the nucleus, 
but p16INK4a immunoreactivity was seen in both the nucleus and the cytoplasm. The mixed 
nuclear and cytoplasmic staining pattern of the p16INK4a protein has been described as a 
mosaic pattern i.e. made up of many small segments (Saito et al., 1999) (Fig.8). 
 
 
Fig.8. Immunohistochemical demonstration of p16INK4a stained cells present in a mosaic 
pattern among cancer cells in squamous cell carcinoma (original magnification x250). 
 
 Epithelium from NOM was divided into two parts: one – to two cell layers close to the 
connective tissue was referred to as the basal cell layer. The rest of the epithelium overlying 
the basal cell layer was designated as the suprabasal cell layer. OED were evaluated in two 
regions of the epithelium, namely the basal part and the superficial part. Specimens of well 
differentiated (WD) and moderately differentiated (MD) OSCC were divided into a one – to 
two cell layers compartment in contact with or close to the surrounding connective tissue 






part comprising more differentiated cells in the centre of tumour islands. This subdivision did 
not apply to poorly differentiated (PD) OSCC because of lack of differentiation and anaplastic 
nature of these tumours. The stained cells were counted at 400X magnification, in 5-10 
randomly selected fields, using a Leica GMBH microscope with a fitted ocular grid. A 
minimum of 1000 cells were counted per slide. The stained cells were scored as a proportion 
of the total cells counted and results were presented as a percentage of positive cells. The 
immunoreactivities were also graded as absent when there was complete lack of staining in 
the tumour cell nuclei, (+) (when there are <10% of the cells stained) and (+ +) (when there 
are  10% of the cells stained). Sections that showed + + immunoreactivities for any of the 




The statistical analysis was performed using SPSS for Windows computer program version 
15.0.1 (SPSS Inc., Chicago, IL, USA) and the graphics were made using commercially 
available computer software (Graph Pad Prism; Graph Pad Software Inc, San Diego, Calif., 
USA). Data are presented as mean (SD). Comparison between two groups was made by using 
two sample t- test and comparison between three groups was made by using a one-way 
analysis of variance (ANOVA), followed up by a post-hoc test where Bonferroni’s correction 
was applied. The chi-square test was used to analyse categorical data. The level of 











One hundred and four subjects had OSCC [(males/females =68/36, mean age: 59.0 (13.7), 
range 16-96 years)]; 20 had OED [(males/females =17/3; mean age: 51.3 (14.8), range 24-73 
years)] and 10 NOM [(males/females =5/5; mean age: 26.3 (6.5), range 22-40)]. Males with 
OSCC were represented in all age groups; however, no female under the age of 20 had OSCC. 





There were no toombak/or alcohol users among the ten patients with NOM, while 90% 
(18/20) were toombak- users and 6 (30%) used alcohol in the OED group. In the OSCC 
group, 79.4 % (54/68) of the males, and 47.2 % (17/36) of the females were toombak users, 
(p=0.001) and only 17.3% (18/104) used alcohol. In the primary sites of toombak application 
(lip, buccal, and floor of mouth), we found that, there is higher incidence of OSCC. This has 
previously been shown by Idris et al. ( 1995a) documenting 375/646 squamous cell 
carcinomas at the primary site of toombak application and its use was more common in people 
with cancers of lip, buccal or floor of mouth compared with other oral sites (58% vs. 19%). 
 
Analysis of p21WAF1 
 
In the NOM, the nuclear staining of p21WAF1 was found in 30% of the cases examined and the 
mean percentage of expression of the protein was found to be 8.6% (Fig.9). The pattern of 
expression was largely confined to the immediate suprabasal region, being frequently detected 






showed 10% (+ +) of expression of p21WAF1 protein and the mean percentage of expression 
was 17.7% (Fig.9). The staining was largely confined to the superficial part, the upper more 
differentiated layers of epithelium, while a low number of p21WAF1expressing cells were 
observed in the basal part. Interestingly, nuclear expression of p21WAF1 was found in the entire 
layer of the OED cases, even the basal cell layer, but most predominantly in the suprabasal 
differentiating cell layer. 
       
Fig.9. Immunohistochemical demonstration of p21WAF1 in oral epithelial dysplasia, stained 
cells were scattered mainly in the suprabasal cell layer, (left panel, original magnification 
x120) (right panel, original magnification x320) 
 
   
 In the OSCCs, the nuclear staining of the p21WAF1was found more pronounced toward 
the peripheral part compared to the central part of the tumour. The p21WAF1 protein nuclear 
staining was found in (96.6%) of the OSCC cases examined and the mean percentage of 
expression was found to be 38.7% (Fig.11). The localization of stained cells was found most 






     
Fig.10. Immunohistochemical demonstration of p21WAF1 in oralsquamous cell carcinoma, 
nuclear stained cells were found more frequent in the peripheral part and less in the central 
part of the tumour nests, (left panel, original magnification x120) (right panel, original 
magnification x250)   
 
 
The expression of p21WAF1 in the sample group showed a significant difference in the 
mean percentage of p21WAF1 between NOM, OED and OSCC (8.6 (3.4), 17.7 (15.2) and 38.7 
(15.8), respectively, (p<0.001). Fig.11. shows the significant difference between NOM and 
OSCC, (p<0.001) and between OED and OSCC, (p<0.001), and a clear trend of increasing 
expression of the protein from NOM to OED to OSCC. 
A chi-square test revealed a significant association between p21WAF1 expression and 
the histological differentiation in OED, (p=0.049) (Table 1), particularly in the toombak users 
(p=0.025) (Table 3). No significant association was found between p21WAF1 expression and 
histological differentiation of the OSCC group (p=0.767) (Table 1). In the OSCC group, a 
significant association was also found between p21WAF1expression and toombak users, 
(p=0.004) (Table 2). In the OSCC group, p21WAF1 expression was significantly higher in the 









Fig.11. The expression of p21WAF1 is shown as mean percentage (Error bar: SD) in Normal 
(NOM), Dysplasia (OED) and Oral Cancer groups (OSCC). 
 
Analysis of p16INK4a 
 
In the NOM group, 9/10 of the cases exhibited nuclear/ cytoplasmic immunostaining of 
p16INK4a protein. The mean percentage of expression of p16INK4a was found to be 25.1% 
(Fig.15). The immunoreactivity for p16INK4a was observed in the basal cell layer. 
In the OED, the expression of 16INK4a was found to be absent in 7 (35%) of the cases. The 
epithelia with moderate and severe dysplasia showed clear stained cells being scattered 







       
 
Fig.12. Immunohistochemical demonstration of p16INK4a stained cells in dysplastic 
epithelium, stained cell are scattered in the basal part of the epithelium (left panel, original 
magnification x120) (right panel, original magnification x250) 
. 
 
 In both OED and OSCCs, cells with p16INK4a protein expression were found present 
only in the mosaic pattern among dysplastic cells and cancer cells. In the OSCCs, staining 
was confined predominantly to the central keratinized cell pearls. Some isolated neoplastic 
cells were also found to be strongly stained (Fig.13). 
 
Fig.13. Demonstration of p16INK4a stained cells present in a mosaic pattern among cancer cells 
in squamous cell carcinoma staining was confined predominantly to the central keratinized 







  There was a lack of p16INK4a protein expression in 52 of the 104 (50%) cases of OSCC 
examined. The majority of these sections demonstrated both nuclear and cytoplasmic staining 
in the tumour cells, scattered nuclear positivity for p16INK4a protein was also observed at the 




Fig.14. Scattered nuclear and cytoplasmic stained cells of p16INK4a in squamous cell 
carcinoma (original magnification x250). 
 
The statistical test showed an overall difference in p16INK4a expression percentage 
between pairs of groups, with a trend of decreasing expression of the protein from NOM to 
OED to OSCC 25.1 (15.0), 8.64 (10.4) and7.60 (13.2), (p=0.001). The statistical significant 
differences are reflected between NOM and OSCC (p=0.001) and between NOM and OED 
(p=0.006) (Fig.15). 
In the OSCC group, a significant association was found between p16INK4a expression 
and histological differentiation (p=0.031) (Table 1). No significant association was found 
between p16INK4a expression and histological differentiation in the OED group (p=0.270) or 
between p16INK4a expression and toombak- use (p=0.521). However in relation to the 
histological differentiation in the OSCC group, a significant association was found between 





































Fig.15. The expression of p16INK4a is shown as mean percentage (Error bar: SD) in Normal 
(NOM), Dysplasia (OED) and Oral Cancer groups (OSCC). 
 
Analysis of Cyclin D1 
 
In normal oral mucosa, the mean percentage of expression of Cyclin D1 was found to be 7.4% 
being detectable in all NOM samples and was observed in the suprabasal cell layers. 
Out of 20 OED cases, 19 (95%), showed abundant of Cyclin Dl expression, in which various 
numbers of nuclear stained cells were identified more frequently than in normal epithelia. 
They clearly appeared in the supra basal cell layer as shown in (Fig.16). 
Different from p21WAF1, Cyclin Dl nuclear staining was found in the majority of the 
tumour cells of OSCCs, and most abundantly in the peripheral part of the tumour. Strongly- 
stained tumour cells were found distributed in the periphery of tumour nests of the well 
differentiated OSCCs as shown in (Fig.17). Expression of Cyclin Dl was found in all of the 









                    
 
Fig.16. Immunohistochemical demonstration of Cyclin Dl nuclear stained cells in the basal 
cell layer of oral epithelial dysplasia (left panel, original magnification x120) (middle panel, 
original magnification x250) (right panel, original magnification x320)   
    
  
      
Fig.17. Immunohistochemical demonstration of Cyclin Dl nuclear stained cells distributed in 
the periphery of tumour nests of oral squamous cell carcinoma (left panel, original 
magnification x120) (right panel, original magnification x320). 
 
  
There was a significant difference in the mean percentage of Cyclin Dl expression all 






and 67.0 (11.0)) (p<0.001), (Fig.18). Similar to p21WAF1, Cyclin Dl showed a trend of 
increasing expression from NOM to OED to OSCC, but with even higher value of percentage 

































Fig.18. The mean expression percentage (Error bar: SD) of expression of Cyclin Dl in Normal 
(NOM), Dysplasia (OED) dysplasia and in the Oral cancer (OSCC) groups. 
 
 
 The results of the immunohistochemical expression of the proteins p21WAF1, p16INK4a 


























































Fig.19. Shows mean percentage (Error bar: SD) of expression of p21WAF1, p16INK4a and Cyclin 










In this work, the expression of some of the G1-S cell cycle regulatory proteins was examined 
in normal, potentially malignant, and malignant oral lesion in association with toombak- use. 
We found that there was significant difference in p21WAF1, p16INK4a and Cyclin D1 
expressions between NOM, OED and OSCC, with high expression of p21WAF1 and Cyclin D1, 
but a low expression of p16INK4a in the OSCCs examined, p21WAF1 expression was found to be 
significantly higher in the toombak users compared with non-users (p=0.004), and a 
significant association was also found between p21WAF1 expression and the histological 
differentiation of OED (p=0.049). However, no difference was found between expressions of 
Cyclin D1 in association with toombak- use.  
 Referring to the gender and toombak use, 19/39 females were toombak- users, this 
means that only 21% (19/89) of the users are actually females. As toombak use is considered 
as a social stigma in Sudan, its use is uncommon among females. This is why oral cancer due 
to toombak use is gender-specific mostly restricted to men. 
 The harmful effects of toombak on the oral mucosa have been suggested by various 
epidemiological studies (Elbeshir et al., 1989; Idris et al., 1994; Idris et al., 1995a; Idris et al., 
1995b). To the best of our knowledge, this is the first study that shows the possible effect of 
toombak on the expression of p21WAF1, p16INK4a and Cyclin D1 in OSCCs from toombak 
users. Expression of p53 protein has been examined in snuff induced oral lesions by 
immunohistochemical analysis (Ibrahim et al., 1997). Moreover, p53 mutations has been 
reported in oral squamous cell carcinomas from ST consumers (snuff dippers from USA, 
Sudan, Norway, Sweden and tobacco chewers from South Asia including India) 
(Warnakulasuriya and Ralhan, 2007). 






wherein exposure of the entire oral cavity to toombak carcinogens may result in field 
cancerization (Strong et al., 1984; Braakhuis et al., 2003). Absence of p16INK4a expression 
was seen in 35% of the oral tissues obtained from patients with potentially malignant lesions 
and in 50% of the OSCCs. These findings might suggest that lack of p16INK4a expression may 
precede histological changes in the oral mucosa. Our data support the previous report that 
p16INK4a is the earliest gene known to be inactivated in head and neck SCCs 
(Papadimitrakopoulou et al., 1997). On the other hand, accumulation of the p21WAF1 was 
observed in 60% and 96.6 % of the oral tissues obtained from the OED and the OSCC  lesions 
respectively, suggesting that alterations in of gene/gene product might occur in later stages of 
oral carcinogenesis. 
 An interesting finding of the present study was the sequential increase in Cyclin D1 
and p21WAF1 expression from histological NOM, to, OED and OSCC. Low expression of 
p16INK4a and increased expression of Cyclin D1 in dysplastic lesions OED may lead to 
increased cell proliferation. These observations corroborate other studies in preinvasive 
lesions of the upper aero digestive tract, wherein it has been shown that Cyclin D1 
deregulation was associated with an increased risk for the development of cancer and with the 
histological progression of this pathology (Uhlman et al., 1996). Experimental evidence have 
also suggested that Cyclin D1 can function as an oncogene and that increased expression of 
Cyclin D1 accelerates the G 1 to S phase transition and likely provides a proliferative 
advantage to tumour cells (Jiang et al., 1993; Sherr, 1994; Izzo et al., 1998). Izzo et al. 
showed that Cyclin D1 gene was amplified in 7 of 10 cases, which progressed from 
potentially malignant oral lesions to invasive carcinoma (Izzo et al., 1998). Over expression 
of Cyclin D1 has been shown to occur early in the development of head and neck 






It has been previously shown that p21WAF1 was over expressed in OSCC (Agarwal et 
al., 1998) and in lower lip SCCs (Horta et al., 2007), although down regulation of p21WAF1 
was seen in patients with tongue SCC (Sathyan et al., 2006). In spite of its over expression, 
P21WAF1 seems to be unable to arrest tumour progression in OSCC (Neves et al., 2004). 
However, the mechanisms allowing proliferation despite the presence of accumulated 
p21WAF1 remains unknown (Affolter et al., 2005). Other studies suggest additional roles for 
p21WAF1 in apoptosis, independent of its role as a cell cycle inhibitor. Thus p21WAF1 is 
probably involved in other functions including inhibition of apoptosis rather than inhibition of 
cell cycle progression (Kudo et al., 1999). It has been reported that there is a lower apoptotic 
rat in OSCC from Sudan compared with those from Norway (Loro et al., 2000). Our finding 
of over expression of p21WAF1in OSCC patients who are toombak users further demonstrates 
that p21WAF1 may play an important role during the pathogenesis of OSCC by affecting 
apoptosis and hence favouring uncontrolled cell proliferation leading to cancer. Components 
of tobacco, including the polycyclic aromatic hydrocarbons (PAH), nicotine and the TSNAs 
have been found to have specific effects on cell cycle arrest at the G0/G1 phase, probably by 
increasing the expression of p21WAF1 (Lee et al., 2005). Considering the unusually high levels 
of the TSNAs found in toombak, high incidence of p53 gene mutations in OSCC from 
toombak users has been reported (Ibrahim et al., 1999). Thus p21WAF1 together with p53, may 
be target genes of oral carcinogenesis in OSCC from toombak users, with the TSNAs possibly 
acting as a principal carcinogen in these types OSCC (Ibrahim et al., 2002).  
The tumour suppressor protein p16INK4a is one of the most direct links between cell-
cycle control and cancer (Serrano, 1997). The p16INK4a gene is frequently inactivated in 
human tumours, and inheritance of mutant alleles results in susceptibility to several types of 






tumour samples has been shown in our study, suggesting that abnormalities of the p16INK4a 
protein may be closely associated with the pathogenesis of OSCC. Down regulation of the 
p16INK4a protein has been found to play an important role in the generation of cancer (Kato et 
al., 2000). It has been found that head and neck SCC were p16INK4a immunostaining- negative 
and that the absence of p16INK4a immunostaining was correlated with a homozygous deletion 
or hypermethylation of the p16INK4a gene promoter (Reed et al., 1996). Reed et al. reported 
that twenty-four out of 29 (83%) head and neck squamous cell carcinoma tumours displayed a 
complete absence of p16INK4a nuclear staining (Reed et al., 1996). He also stated that 
immunohistochemical analysis for expression of the p16INK4a gene product is an accurate and 
relatively simple method for evaluating p16INK4a gene inactivation. In addition, Geradtes et al 
reported that immunohistochemical analysis is a straightforward method to detect p16INK4a 
inactivation regardless of the precise genetic mechanism involved (Geradts et al., 1995). 
Inactivation of p16INK4a occurs at the early stage of oral mucosal dysplasia in the multistep 
process of oral tumourgenesis. The high frequency of deletions of p16INK4a in tumour cell lines 
first suggested an important role for p16INK4a in carcinogenesis. This initial genetic evidence 
was subsequently strengthened by numerous studies documenting p16INK4a inactivation in 
several human cancers. It is now believed that loss of p16INK4a is an early and often critical 
event in tumour progression (Pande et al., 1998). Although p16INK4a may be involved in cell 
senescence, the physiologic role of p16INK4a is still unclear. 
This study has found that Cyclin D1 protein is over-expressed in OSCC examined, 
with no difference in regards to toombak- use. This suggests that Cyclin D1 could play a role 
in the development of OSCCs by providing a growth advantage for severe epithelial 
dysplasia, thus supporting its role in proliferative activity. 






(26.7%) toombak users 4out of 15 moderate / severe dysplasias. One of the interesting 
findings of this study is the observation that 18 out of the 20 potentially malignant lesions 
examined (90%) were from toombak users with altered expression of all the three markers 
examined. This suggests that altered expression of these proteins may lead to malignant 
transformation of these lesions. It is worthwhile noting that the percentage of dysplasia that 
progresses to malignant lesion has been shown to vary from 5 to 43% related to the severity of 
dysplasia (Rocco and Sidransky, 2001). Considering these observations, our findings might 
suggest that chronic toombak users may be at risk for developing malignancy when changes 
of the proteins examined can be detected in potentially malignant lesion obtained from these 
users. Based on these observations, we propose that dysplastic lesions harbouring concomitant 
alterations in expression of these markers may be at high risk for transition to malignancy in 
habitual toombak -users from Sudan. 
In conclusion, the results of the present study shows that the p21WAF1 protein is 
significantly over expressed in OSCCs and especially in those from toombak users. However, 
p16INK4a expression was considerably low and Cyclin D1 is over expressed in all the OSCCs 
examined. Alternations in these proteins may play a role in oral carcinogenesis and may be 
used as biomarkers in potentially malignant and malignant oral lesions from habitual users of 
toombak. The findings of low expression of p16INK4a might indicate that it is one of the 
earliest events in the process of development of oral cancer, and that Cyclin D1 over 
expression is an important event in the acquisition of the potentially malignant lesions. 
There is very little data related to the biological markers in oral cancer lesions from 
African populations, in particular Sudanese toombak - dippers and non - dippers. However, 
there is now an opportunity in Sudan to study oral cancer associated with toombak, and thus 






The magnitude of the problem of oral cancer in Sudan obliges identification of early 
signs and symptoms, so that preventive and curative measures can be followed. This involves 
education of oral health workers on signs and symptoms of potentially malignant and 
malignant oral lesions and methods that can be used for early detection to characterise the 
damage induced by toombak either in short or long- term use of toombak. This may help in 
determining the internal dose of exposure and disease risk, or may predict early biological 
changes associated with the development of oral cavity lesions. 
 Research oriented methods for detection and characterisation of these lesions would 
eventually increase the public awareness and knowledge of long standing toombak- induced 
lesions and oral cancer in the area. 
 The major challenge to treatment of cancer in Sudan, as in most developing countries, 
is that most patients first present with advanced stage disease. A total of 78% of the Sudanese 
patients have stage III or IV disease (TNM classification) when they first seek medical 
treatment (Hamad, 2006). In these stages, treatment may often involve multiple modalities, 
including surgery, radiotherapy, chemotherapy and hormone therapy, and has a markedly 
diminished chance of success. In addition, cancers like oral cancer are largely curable if 
detected early. Therefore, there is an urgent need for  applying methods that might help in 
early detection of oral cancer in Sudan, especially in those at high risk to develop  the disease 
(toombak- users), to make treatment more effective, less costly, less invasive, and more 







Table 1. Relationship between expression of p21WAF1, p16INK4a and Cyclin D1 and histological differentiation in oral epithelial dysplasia (OED) 
and oral squamous cell carcinomas (OSCCs) 
 
  P21WAF1expression n (%) p16INK4 expression n (%) Cyclin D1 expression n (%) 
OED <10% (+) 10% (++) <10% (+) 10% (++)  <10% (+) 10% (++) 
Dysplasia (Histology) (n =20)       
Mild (n=3) 3 (100) 0 (0) 1 (33.3) 2 (66.7) 0 (0) 3 (100) 
Moderate/ severe (n=17) 5 (29.4) 12 (70.6) 12 (70.6) 5 (29.4) 1 (5.9) 16 (94.1) 
p-value  0.049*  0.270   
OSCC (Histology) (n=104)       
Well differentiated (n=89) 8 (9.0) 81 (91.0) 72(80.9) 17 (19.1) 0 (0) 89 (100) 
Moderately/ Poorly 
differentiated (n=15) 
1 (6.7) 14 (93.3) 8(53.3) 7 (46.7) 0 (0) 15 (100) 
p-value  0.767  0.031*   




Table 2. Relationship between expression of p21WAF1, p16INK4a and Cyclin D1 and toombak- use in oral epithelial dysplasia (OED) and 
oral squamous cell carcinomas (OSCCs) 
 
  p21WAF1expression n (%) p16INK4 expression n (%) Cyclin D1 expression n (%) 
OED <10% (+) 10% (++) <10% (+) 10% (++) <10% (+) 10% (++) 
Dysplasia (toombak- use)        
Users (n=18) 6 (33.3) 12 (66.7) 11 (61.1) 7 (38.9) 1 (5.6) 17 (94.4) 
Non-users (n=2) 2 (100) 0 (0) 2(100) 0 (0) 0 (0) 2 (100) 
p-value  0.147  0.521   
OSCC (toombak- use)       
Users (n=71) 2(2.8) 69 (97.2) 53 (74.6) 18 (25.4) 0 (0) 71 (100) 
Non-users (n=33) 7 (21.2) 26 (78.8) 27 (81.8) 6 (18.2) 0 (0) 33 (100) 
p-value  0.004*  0.465   
 





Table 3 Relationship between expression of p21WAF1, p16INK4a and Cyclin D1 in toombak users according to histological differentiation 
of oral epithelial dysplasia (OED) and oral squamous cell carcinomas (OSCCs). 
 
Toombak users p21WAF1expression n (%) p16INK4 expression n (%) Cyclin D1 expression n (%) 
 OED <10% (+) 10% (++) <10% (+) 10% (++) <10% (+) 10% (++) 
Dysplasia (n=18)       
Mild (n=3) 3 (100) 0 (0)  1 (33.3) 2 (66.7) 0 (0) 3 (100) 
Moderate/ severe (n=15) 3 (20) 12 (80) 10 (66.7) 5 (33.3) 1 (6.7) 14 (93.3) 
p-value  0.025*  0.528   
OSCCs (n=71)       
Well differentiated (n=62) 2 (3.2) 60 (96.8) 49(79) 13 (21) 0 (0) 62(100) 
Moderately/ Poorly differentiated (n=9) 0 (0) 9(100) 4 (44.4) 5 (55.6) 0 (0) 9 (100) 
p-value  > 0.8  0.040*   
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